Skip to main content
  • Saved

Commented on 's Post

Safety and tolerability evaluation of erenumab for the preventive treatment of migraine

Safety and tolerability evaluation of erenumab for the preventive treatment of migraine

Source :

https://www.tandfonline.com/doi/abs/10.1080/14740338.2021.1933941

Abstract Introduction: Erenumab, a monoclonal antibody targeting the receptor of calcitonin gene related peptide (CGRP), is the first disease-specific and mechanism-based treatment approved for the prevention of migraine. Although the safety and tolerability data from randomized trials are clear, the physiological effects of CGRP rise reasonable concerns.